{"entity":{"id":"tpst-2003","kind":"drug","name":"TPST-2003","aka":[],"tldr":"TPST-2003 is a CAR-T cell treatment, made from a patient's own immune cells, from Tempest Therapeutics. It targets two markers and is being tested in multiple myeloma that has come back.","summary":"TPST-2003 is an autologous CD19 and BCMA CAR-T therapy whose rights Tempest Therapeutics acquired in February 2026. Tempest describes it as in clinical development for relapsed or refractory multiple myeloma and for POEMS syndrome, a rare plasma cell disorder; the filing does not state the phase.","asOf":"2026-11-04","links":[{"label":"SEC: Tempest Therapeutics Form S-1, August 2026","url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526361240/d181522ds1.htm"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":["cd19","bcma"],"drugs":[],"companies":["tempest-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"TPST-2003","modality":"Autologous CAR-T (dual CD19 and BCMA)","mechanism":"An autologous T cell therapy carrying a dual-targeting CD19 and BCMA chimeric antigen receptor, as described by Tempest Therapeutics.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tpst-2003/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"tempest-therapeutics","kind":"company","name":"Tempest Therapeutics","route":"/companies/tempest-therapeutics/"}]}}